Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women

Journal of the National Cancer Institute

Volumn 108, Issue 10, 2016, Pages

  Moore, Steven C ^a   Matthews, Charles E ^b   Ou Shu, Xiao ^c   Yu, Kai ^d   Gail, Mitchell H ^e   Xu, Xia ^f   Ji, Bu Tian ^d   Chow, Wong Ho ^c   Cai, Qiuyin ^c   Li, Honglan ^b   Yang, Gong ^a   Ruggieri, David ^b   Boyd Morin, Jennifer ^b   Rothman, Nathaniel ^b   Hoover, Robert N ^c   Gao, Yu Tang ^d   Zheng, Wei ^b   Ziegler, Regina G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d SHANGHAI CANCER INSTITUTE   (China)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; ESTRADIOL; ESTROGEN; ESTRONE;

ADULT; AGED; ARTICLE; ASIAN AMERICAN; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CHINESE; CONTROLLED STUDY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HUMAN; HYDROXYLATION; KIDNEY CONCENTRATING CAPACITY; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; BREAST NEOPLASMS; CASE CONTROL STUDY; CHINA; INCIDENCE; METABOLISM; MIDDLE AGED; ODDS RATIO; UNITED STATES; URINE;

AGED; ASIAN AMERICANS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; INCIDENCE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; UNITED STATES;

EID: 84994247393     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw103     Document Type: Article

References (52)

1. Doll R, Payne P, Waterhouse J. Cancer Incidence in Five Continents, Vol. 1. Union Internationale Contre le Cancer, Geneva, Switzerland: 1966.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. 2013.
3. Ziegler RG, Anderson WF, Gail MH. Increasing breast cancer incidence in China: the numbers add up. J Natl Cancer Inst. 2008;100 (19):1339-1341.
4. Ziegler RG, Hoover RN, Pike MC, et al. Migration patterns and breast cancer risk in Asian American women. J Natl Cancer Inst. 1993;85 (22):1819-1827.
5. Gomez SL, Noone AM, Lichtensztajn DY, et al. Cancer incidence trends among Asian American populations in the United States, 1990-2008. J Natl Cancer Inst. 2013;105 (15):1096-1110.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet. 2002;360 (9328):187-195.
7. Linos E, Spanos D, Rosner BA, et al. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst. 2008;100 (19):1352-1360.
8. Hoover RN. That recognised risk factors can explain past and present international differences in breast cancer incidence: misconceptions 5. Br J Cancer. 2012;107 (3):408-410.
9. Cole P, MacMahon B. Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969;1 (7595):604-606.
10. Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci U S A. 1988;85 (21):7831-7835.
11. Seeger H, Wallwiener D, Kraemer E, Mueck AO. Comparison of possible carcinogenic estradiol metabolites: effects on proliferation, apoptosis and metastasis of human breast cancer cells. Maturitas. 2006;54 (1):72-77.
12. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006;147 (9):4132-4150.
13. Kono S, Merriam GR, Brandon DD, Loriaux DL, Lipsett MB, Fujino T. Radioimmunoassay and metabolic clearance rate of catecholestrogens, 2-hydroxyestrone and 2-hydroxyestradiol in man. J Steroid Biochem. 1983;19 (1B):627-633.
14. Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta. 2006;1766 (1):63-78.
15. Lavigne JA, Goodman JE, Fonong T, et al. The effects of catechol-O-methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells. Cancer Res. 2001;61 (20):7488-7494.
16. Meilahn EN, De SB, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer. 1998;78 (9): 1250-1255.
17. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000;11 (6):635-640.
18. Cauley JA, Zmuda JM, Danielson ME, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology. 2003;14 (6):740-744.
19. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev. 2005;14 (9):2137-2142.
20. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxyand 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008;17 (8):2029-2035.
21. Mackey RH, Fanelli TJ, Modugno F, et al. Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. Cancer Epidemiol Biomarkers Prev. 2012;21 (11):2022-2032.
22. Arslan AA, Koenig KL, Lenner P, et al. Circulating estrogen metabolites and risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2014;23 (7):1290-1297.
23. Handelsman DJ, Wartofsky L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab. 2013;98 (10):3971-3973.
24. Stanczyk FZ, Clarke NJ. Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol. 2010;121 (3-5):491-495.
25. Eliassen AH, Spiegelman D, Xu X, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res. 2012;72 (3):696-706.
26. Fuhrman BJ, Schairer C, Gail MH, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012;104 (4):326-339.
27. Dallal CM, Tice JA, Buist DS, et al. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B-FIT. Carcinogenesis. 2014;35 (2):346-355.
28. Falk RT, Brinton LA, Dorgan JF, et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: a nested case-control study. Breast Cancer Res. 2013;15 (2):R34.
29. Ziegler RG, Faupel-Badger JM, Sue LY, et al. A new approach to measuring estrogen exposure and metabolism in epidemiologic studies. J Steroid Biochem Mol Biol. 2010;121 (3-5):538-545.
30. Ziegler RG, Fuhrman BJ, Moore SC, Matthews CE. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids. 2015;99 (Pt A):67-75.
31. Ursin G, Wilson M, Henderson BE, et al. Do urinary estrogen metabolites reflect the differences in breast cancer risk between Singapore Chinese and United States African-American and white women? Cancer Res. 2001;61 (8):3326-3329.
32. Key TJ, Chen J, Wang DY, Pike MC, Boreham J. Sex hormones in women in rural China and in Britain. Br J Cancer. 1990;62 (4):631-636.
33. Zheng W, Chow WH, Yang G, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol. 2005;162 (11):1123-1131.
34. Fuhrman BJ, Feigelson HS, Flores R, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014;99 (12):4632-4640.
35. Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG. A liquid chromatographymass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: assay reproducibility and interindividual variability. Cancer Epidemiol Biomarkers Prev. 2008;17 (12): 3411-3418.
36. Fuhrman BJ, Brinton LA, Pfeiffer RM, et al. Estrogen metabolism and mammographic density in postmenopausal women: a cross-sectional study. Cancer Epidemiol Biomarkers Prev. 2012;21 (9):1582-1591.
37. Fuhrman BJ, Xu X, Falk RT, et al. Stability of 15 estrogens and estrogen metabolites in urine samples under processing and storage conditions typically used in epidemiologic studies. Int J Biol Markers. 2010;25 (4).
38. Xu X, Veenstra TD, Fox SD, et al. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatographymass spectrometry. Anal Chem. 2005;77 (20):6646-6654.
39. Key TJ, Appleby PN, Reeves GK, et al. Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids. 2015;99 (Pt A):49-55.
40. Key TJ, Wang DY, Brown JB, et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer. 1996;73 (12):1615-1619.
41. Onland-Moret NC, Kaaks R, van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer. 2003;88 (9):1394-1399.
42. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94 (8):606-616.
43. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95 (16):1218-1226.
44. Rinaldi S, Key TJ, Peeters PH, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer. 2006;118 (11):2832-2839.
45. Gunter MJ, Wang T, Cushman M, et al. Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. J Natl Cancer Inst. 2015;107 (9):djv169.
46. Schairer C, Fuhrman BJ, Boyd-Morin J, et al. Quantifying the Role of Circulating Unconjugated Estradiol in Mediating the Body Mass Index-Breast Cancer Association. Cancer Epidemiol Biomarkers Prev. 2016;25 (1):105-113.
47. MacMahon B, Cole P, Brown JB, et al. Oestrogen profiles of Asian and North American women. Lancet. 1971;2 (7730):900-902.
48. Shimizu H, Ross RK, Bernstein L, Pike MC, Henderson BE. Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan. Br J Cancer. 1990;62 (3):451-453.
49. Hayward JL, Greenwood FC, Glober G, et al. Endocrine status in normal British, Japanese and Hawaiian-Japanesewomen. Eur J Cancer. 1978;14 (11):1221-1228.
50. Beckmann L, Husing A, Setiawan VW, et al. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre-and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab. 2011;96 (2): E360-E367.
51. Boyapati SM, Shu XO, Gao YT, et al. Correlation of blood sex steroid hormones with body size, body fat distribution, and other known risk factors for breast cancer in post-menopausal Chinese women. Cancer Causes Control. 2004;15 (3):305-311.
52. Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol. 1982;59 (6):680-686.